188.20
-1.40
(-0.74%)
At close: January 31 at 5:27:10 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
761,000.00
761,000.00
1,119,000.00
1,553,000.00
1,081,000.00
Investing Cash Flow
-440,000.00
-440,000.00
-1,580,000.00
-487,000.00
-2,228,000.00
Financing Cash Flow
-308,000.00
-308,000.00
70,000.00
-1,119,000.00
1,177,000.00
End Cash Position
861,000.00
861,000.00
859,000.00
1,244,000.00
1,303,000.00
Capital Expenditure
-316,000.00
-316,000.00
-371,000.00
-493,000.00
-349,000.00
Issuance of Capital Stock
--
--
--
--
150,000.00
Issuance of Debt
597,000.00
597,000.00
1,025,000.00
--
1,895,000.00
Repayment of Debt
-424,000.00
-424,000.00
-546,000.00
-716,000.00
-416,000.00
Repurchase of Capital Stock
-40,000.00
-40,000.00
-42,000.00
-60,000.00
-106,000.00
Free Cash Flow
445,000.00
445,000.00
748,000.00
1,060,000.00
732,000.00
12/31/2020 - 5/15/2001
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
1AEA.SG argenx SE
635.00
+2.42%
1AE.SG argenx SE
637.80
+1.75%
ARGX.VI argenx SE
642.80
+1.61%
LVTX LAVA Therapeutics N.V.
0.9800
+3.62%
ARGX argenx SE
655.13
-1.58%
CORT Corcept Therapeutics Incorporated
66.92
-4.26%
PPCB Propanc Biopharma, Inc.
9.00
0.00%
AKRO Akero Therapeutics, Inc.
54.08
-2.31%